D.E. Shaw & Co
AUTL

D.E. Shaw & Co’s Autolus Therapeutics AUTL Stock Holding History

D.E. Shaw & Co’s Portfolio AUTL Stock Details AUTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-91,687
Closed -$333K – 4404
2024
Q3 		$333K Sell
91,687
-491,178
-84% -$1.96M ﹤0.01% 3927
2024
Q2 		$2.03M Sell
582,865
-64,094
-10% -$277K ﹤0.01% 2647
2024
Q1 		$4.13M Buy
646,959
+425,470
+192% +$2.65M ﹤0.01% 2031
2023
Q4 		$1.43M Buy
+221,489
New +$845K ﹤0.01% 2900
2021
Q3 		– Sell
-32,500
Closed -$216K – 4952
2021
Q2 		$216K Buy
+32,500
New +$202K ﹤0.01% 4419

Other funds holding AUTL

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return
SP
Syncona Portfolio St Peter Port, Guernsey $25.7M AUM 13.32% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
TAM
TFG Asset Management Grand Cayman, Cayman Islands $515M AUM 24.47% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return

D.E. Shaw & Co's AUTL Position: Q4 2024 in Review

D.E. Shaw & Co sold out of Autolus Therapeutics (AUTL) in Q4 2024, closing a stake of 91,687 shares — an estimated $333K sold.

D.E. Shaw & Co first reported a position in AUTL in Q2 2021 and held it in 5 quarters. The position peaked at $4.13M in Q1 2024. 110 funds tracked by Wall St. Rank hold AUTL as of Q4 2024.

  • D.E. Shaw & Co reported no remaining Autolus Therapeutics position as of Q4 2024 after selling out during the quarter.
  • D.E. Shaw & Co sold 91,687 Autolus Therapeutics shares in Q4 2024, an estimated $333K.
  • D.E. Shaw & Co first reported a position in Autolus Therapeutics in Q2 2021 and held it in 5 quarters.
  • D.E. Shaw & Co's Autolus Therapeutics position peaked at $4.13M in Q1 2024.
  • 110 funds tracked by Wall St. Rank held Autolus Therapeutics as of Q4 2024.

Based on D.E. Shaw & Co's 13F filing for Q4 2024, filed 14 Feb 2025.